newsfilter
← Latest News
Business Wire·

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

Positive one year challenge data builds on previously reported efficacy observed at 28- and 90-day challenge timepoints Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug developm